Search

Your search keyword '"Carrasco-Alfonso, Marlene"' showing total 36 results
Start Over Author "Carrasco-Alfonso, Marlene"
36 results on '"Carrasco-Alfonso, Marlene"'

1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Author

Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

2. Genetic and epigenetic fine mapping of causal autoimmune disease variants

Author

Farh, Kyle Kai-How, Marson, Alexander, Zhu, Jiang, Kleinewietfeld, Markus, Housley, William J, Beik, Samantha, Shoresh, Noam, Whitton, Holly, Ryan, Russell JH, Shishkin, Alexander A, Hatan, Meital, Carrasco-Alfonso, Marlene J, Mayer, Dita, Luckey, C John, Patsopoulos, Nikolaos A, De Jager, Philip L, Kuchroo, Vijay K, Epstein, Charles B, Daly, Mark J, Hafler, David A, and Bernstein, Bradley E

Subjects
Immunization, Human Genome, Vaccine Related, Autoimmune Disease, Genetics, 1.1 Normal biological development and functioning, 2.1 Biological and endogenous factors, Aetiology, Underpinning research, Inflammatory and immune system, Autoimmune Diseases, Base Sequence, Chromatin, Consensus Sequence, Enhancer Elements, Genetic, Epigenesis, Genetic, Epigenomics, Genome-Wide Association Study, Humans, Nucleotide Motifs, Organ Specificity, Polymorphism, Single Nucleotide, T-Lymphocytes, Transcription Factors, General Science & Technology
Abstract

Genome-wide association studies have identified loci underlying human diseases, but the causal nucleotide changes and mechanisms remain largely unknown. Here we developed a fine-mapping algorithm to identify candidate causal variants for 21 autoimmune diseases from genotyping data. We integrated these predictions with transcription and cis-regulatory element annotations, derived by mapping RNA and chromatin in primary immune cells, including resting and stimulated CD4(+) T-cell subsets, regulatory T cells, CD8(+) T cells, B cells, and monocytes. We find that ∼90% of causal variants are non-coding, with ∼60% mapping to immune-cell enhancers, many of which gain histone acetylation and transcribe enhancer-associated RNA upon immune stimulation. Causal variants tend to occur near binding sites for master regulators of immune differentiation and stimulus-dependent gene activation, but only 10-20% directly alter recognizable transcription factor binding motifs. Rather, most non-coding risk variants, including those that alter gene expression, affect non-canonical sequence determinants not well-explained by current gene regulatory models.

Published
2015

3. P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C

Author

Alsina, Melissa, primary, Dhodapkar, Madhav, additional, Berdeja, Jesus, additional, Patel, Krina, additional, Richard, Shambavi, additional, Vij, Ravi, additional, Leleu, Xavier, additional, Egan, Daniel, additional, Leif Bergsagel, P., additional, Ran, Reshef, additional, Usmani, Saad Z, additional, Truppel-Hartmann, Anna, additional, Basudhar, Debashree, additional, Thompson, Ethan, additional, Zheng, Xirong, additional, Zhong, Xiaobo, additional, Greggio, Chiara, additional, Popa Mckiver, Mihaela, additional, Carrasco Alfonso, Marlene, additional, and Siegel, David, additional

Published
2023
Full Text
View/download PDF

5. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun Young, Lee, Jae-Lyun, Chung, Jinsoo, Lim, Ho Yeong, Wu, Hsi Chin, Chang, Yen Hwa, Azad, Arun, Davis, Ian D., Carrasco-Alfonso, Marlene J., Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Published
2018
Full Text
View/download PDF

7. P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma

Author

Einsele, Hermann, primary, Parekh, Samir, additional, Madduri, Deepu, additional, Santomasso, Bianca, additional, Pérez-Larraya, Jaime Gállego, additional, van de Donk, Niels W.C.J., additional, Arnulf, Bertrand, additional, Mateos, María-Victoria, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lendvai, Nikoletta, additional, Jackson, Carolyn C., additional, Olyslager, Yunsi, additional, Zudaire, Enrique, additional, Li, Claire, additional, Geng, Dong, additional, Jakubowiak, Andrzej, additional, and Cohen, Adam, additional

Published
2021
Full Text
View/download PDF

8. OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2

Author

Cohen, Adam, primary, Agha, Mounzer, additional, Madduri, Deepu, additional, Cohen, Yael, additional, Delforge, Michel, additional, Hillengass, Jens, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Raab, Marc-Steffen, additional, Scheid, Christoph, additional, Schecter, Jordan M., additional, Braganca, Kevin C. De, additional, Varsos, Helen, additional, Wang, Liwei, additional, Vogel, Martin, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Wu, Xiaoling, additional, Nesheiwat, Tonia, additional, and Einsele, Hermann, additional

Published
2021
Full Text
View/download PDF

9. MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel)

Author

Jakubowiak, Andrzej, primary, Parekh, Samir, additional, Madduri, Deepu, additional, Santomasso, Bianca, additional, Pérez-Larraya, Jaime Gállego, additional, van de Donk, Niels W.C.J., additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lendvai, Nikoletta, additional, Jackson, Carolyn C., additional, Olyslager, Yunsi, additional, Zudaire, Enrique, additional, Li, Claire, additional, Geng, Dong, additional, Einsele, Hermann, additional, and Cohen, Adam, additional

Published
2021
Full Text
View/download PDF

10. Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

11. Poster: MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel)

Author

Jakubowiak, Andrzej, primary, Parekh, Samir, additional, Madduri, Deepu, additional, Santomasso, Bianca, additional, Pérez-Larraya, Jaime Gállego, additional, van de Donk, Niels W.C.J., additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lendvai, Nikoletta, additional, Jackson, Carolyn C., additional, Olyslager, Yunsi, additional, Zudaire, Enrique, additional, Li, Claire, additional, Geng, Dong, additional, Einsele, Hermann, additional, and Cohen, Adam, additional

Published
2021
Full Text
View/download PDF

12. Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

13. MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Usmani, Saad Z., primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn C, additional, Allred, Alicia, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

14. Integrative analysis of 111 reference human epigenomes

Author

Consortium, Roadmap Epigenomics, Kundaje, Anshul, Meuleman, Wouter, Ernst, Jason, Bilenky, Misha, Yen, Angela, Heravi-Moussavi, Alireza, Kheradpour, Pouya, Zhang, Zhizhuo, Wang, Jianrong, Ziller, Michael J., Whitaker, John W., Ward, Lucas D., Sarkar, Abhishek, Sandstrom, Richard S., Wu, Yi-Chieh, Pfenning, Andreas R., Wang, Xinchen, Claussnitzer, Melina, Liu, Yaping, Harris, Alan R., Epstein, Charles B., Leung, Danny, Hawkins, David R., Hong, Chibo, Mungall, Andrew J., Chuah, Eric, Hansen, Scott R., Bansal, Mukul S., Dixon, Jesse R., Feizi, Soheil, Kim, Ah-Ram, Li, Daofeng, Elliott, GiNell, Neph, Shane J., Polak, Paz, Ray, Pradipta, Siebenthall, Kyle T., Thurman, Robert E., Zhou, Xin, Boyer, Laurie A., De Jager, Philip L., Fisher, Susan J., Li, Wei, McManus, Michael T., Sunyaev, Shamil, Tlsty, Thea D., Wang, Wei, Waterland, Robert A., Costello, Joseph F., Hirst, Martin, Stamatoyannopoulos, John A., Wang, Ting, Amin, Viren, Schultz, Matthew D., Quon, Gerald, Eaton, Matthew L., Pfenning, Andreas, Liu, Melina ClaussnitzerYaping, Coarfa, Cristian, Shoresh, Noam, Gjoneska, Elizabeta, Xie, Wei, Lister, Ryan, Moore, Richard, Tam, Angela, Canfield, Theresa K., Kaul, Rajinder, Sabo, Peter J., Carles, Annaick, Farh, Kai-How, Karlic, Rosa, Kulkarni, Ashwinikumar, Lowdon, Rebecca, Mercer, Tim R., Onuchic, Vitor, Rajagopal, Nisha, Sallari, Richard C., Sinnott-Armstrong, Nicholas A., Stevens, Michael, Wu, Jie, Zhang, Bo, Abdennur, Nezar, Adli, Mazhar, Akerman, Martin, Barrera, Luis, Antosiewicz-Bourget, Jessica, Ballinger, Tracy, Barnes, Michael J., Bates, Daniel, Bell, Robert J. A., Bennett, David A., Bianco, Katherine, Bock, Christoph, Boyle, Patrick, Brinchmann, Jan, Caballero-Campo, Pedro, Camahort, Raymond, Carrasco-Alfonso, Marlene J., Charnecki, Timothy, Chen, Huaming, Chen, Zhao, Cheng, Jeffrey B., Cho, Stephanie, Chu, Andy, Chung, Wen-Yu, Cowan, Chad, Deng, Qixia Athena, Deshpande, Vikram, Diegel, Morgan, Ding, Bo, Durham, Timothy, Echipare, Lorigail, Edsall, Lee, Flowers, David, Genbacev-Krtolica, Olga, Gifford, Casey, Gillespie, Shawn, Giste, Erika, Glass, Ian A., Gnirke, Andreas, Gormley, Matthew, Gu, Hongcang, Gu, Junchen, Hafler, David A., Hangauer, Matthew J., Hariharan, Manoj, Hatan, Meital, Haugen, Eric, He, Yupeng, Heimfeld, Shelly, Herlofsen, Sarah, Hou, Zhonggang, Humbert, Richard, Issner, Robbyn, Jackson, Andrew R., Jia, Haiyang, Jiang, Peng, Johnson, Audra K., Kadlecek, Theresa, Kamoh, Baljit, Kapidzic, Mirhan, Kent, Jim, Kim, Audrey, Kleinewietfeld, Markus, Klugman, Sarit, Krishnan, Jayanth, Kuan, Samantha, Kutyavin, Tanya, Lee, Ah-Young, Lee, Kristen, Li, Jian, Li, Nan, Li, Yan, Ligon, Keith L., Lin, Shin, Lin, Yiing, Liu, Jie, Liu, Yuxuan, Luckey, John C., Ma, Yussanne P., Maire, Cecile, Marson, Alexander, Mattick, John S., Mayo, Michael, McMaster, Michael, Metsky, Hayden, Mikkelsen, Tarjei, Miller, Diane, Miri, Mohammad, Mukame, Eran, Nagarajan, Raman P., Neri, Fidencio, Nery, Joseph, Nguyen, Tung, OʼGeen, Henriette, Paithankar, Sameer, Papayannopoulou, Thalia, Pelizzola, Mattia, Plettner, Patrick, Propson, Nicholas E., Raghuraman, Sriram, Raney, Brian J., Raubitschek, Anthony, Reynolds, Alex P., Richards, Hunter, Riehle, Kevin, Rinaudo, Paolo, Robinson, Joshua F., Rockweiler, Nicole B., Rosen, Evan, Rynes, Eric, Schein, Jacqueline, Sears, Renee, Sejnowski, Terrence, Shafer, Anthony, Shen, Li, Shoemaker, Robert, Sigaroudinia, Mahvash, Slukvin, Igor, Stehling-Sun, Sandra, Stewart, Ron, Subramanian, Sai Lakshmi, Suknuntha, Kran, Swanson, Scott, Tian, Shulan, Tilden, Hannah, Tsai, Linus, Urich, Mark, Vaughn, Ian, Vierstra, Jeff, Vong, Shinny, Wagner, Ulrich, Wang, Hao, Wang, Tao, Wang, Yunfei, Weiss, Arthur, Whitton, Holly, Wildberg, Andre, Witt, Heather, Won, Kyoung-Jae, Xie, Mingchao, Xing, Xiaoyun, Xu, Iris, Xuan, Zhenyu, Ye, Zhen, Yen, Chia-an, Yu, Pengzhi, Zhang, Xian, Zhang, Xiaolan, Zhao, Jianxin, Zhou, Yan, Zhu, Jiang, Zhu, Yun, Ziegler, Steven, Beaudet, Arthur E., Farnham, Peggy J., Haussler, David, Jones, Steven J. M., Marra, Marco A., Thomson, James A., Tsai, Li-Huei, Zhang, Michael Q., Chadwick, Lisa H., Bernstein, Bradley E., Ecker, Joseph R., Meissner, Alexander, Milosavljevic, Aleksandar, Ren, Bing, and Kellis, Manolis

Published
2015
Full Text
View/download PDF

15. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Author

Agha, Mounzer E., primary, Cohen, Adam D., additional, Madduri, Deepu, additional, Cohen, Yael C., additional, Delforge, Michel, additional, Hillengass, Jens, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Raab, Marc-Steffen, additional, Scheid, Christof, additional, Schecter, Jordan Mark, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Wang, Liwei, additional, Vogel, Martin, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Wu, Xiaoling, additional, Nesheiwat, Tonia, additional, and Einsele, Hermann, additional

Published
2021
Full Text
View/download PDF

16. Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

Author

Einsele, Hermann, primary, Parekh, Samir S., additional, Madduri, Deepu, additional, Santomasso, Bianca, additional, Gállego Pérez De Larraya, Jaime, additional, van de Donk, Niels W.C.J., additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Lendvai, Nikoletta, additional, Jackson, Carolyn Chang, additional, Olyslager, Yunsi, additional, Zudaire, Enrique, additional, Li, Claire, additional, Geng, Dong, additional, Jakubowiak, Andrzej J., additional, and Cohen, Adam D., additional

Published
2021
Full Text
View/download PDF

17. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

Author

Usmani, Saad Zafar, primary, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Jakubowiak, Andrzej J., additional, Agha, Mounzer E., additional, Cohen, Adam D., additional, Hari, Parameswaran, additional, Yeh, Tzu-Min, additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Jackson, Carolyn Chang, additional, Allred, Alicia Jones, additional, Zudaire, Enrique, additional, Deraedt, William, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Lin, Yi, additional, Martin, Thomas G., additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

18. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Author

Agha, Mounzer E., Cohen, Adam D., Madduri, Deepu, Cohen, Yael C., Delforge, Michel, Hillengass, Jens, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan Mark, De Braganca, Kevin C., Varsos, Helen, Wang, Liwei, Vogel, Martin, Carrasco-Alfonso, Marlene, Akram, Muhammad, Wu, Xiaoling, Nesheiwat, Tonia, Einsele, Hermann, Agha, Mounzer E., Cohen, Adam D., Madduri, Deepu, Cohen, Yael C., Delforge, Michel, Hillengass, Jens, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan Mark, De Braganca, Kevin C., Varsos, Helen, Wang, Liwei, Vogel, Martin, Carrasco-Alfonso, Marlene, Akram, Muhammad, Wu, Xiaoling, Nesheiwat, Tonia, and Einsele, Hermann

Published
2021

19. CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma

Author

Einsele, Hermann, primary, van de Donk, Niels W.C.J., additional, Arnulf, Bertrand, additional, Schecter, Jordan M., additional, De Braganca, Kevin C., additional, Varsos, Helen, additional, Deraedt, William, additional, Tian, Hong, additional, Vogel, Martin, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Wu, Xiaoling, additional, Nesheiwat, Tonia, additional, Mateos, Maria-Victoria, additional, and Usmani, Saad Z., additional

Published
2021
Full Text
View/download PDF

20. Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Author

Cohen, Adam D., primary, Hari, Parameswaran, additional, Htut, Myo, additional, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Usmani, Saad Z., additional, Allred, Alicia J., additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Schecter, Jordan M., additional, Jackson, Carolyn C., additional, Gries, Katharine S., additional, Fastenau, John, additional, Deraedt, William, additional, Carrasco-Alfonso, Marlene J., additional, Akram, Muhammad, additional, Hossain, Farah, additional, Crawford, Rebecca, additional, Morrison, Ross, additional, Doward, Lynda, additional, Jakubowiak, Andrzej, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

21. Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study

Author

Lin, Yi, primary, Martin, Thomas, additional, Cohen, Adam D., additional, Jakubowiak, Andrzej, additional, Jasielec, Jagoda, additional, Usmani, Saad Z., additional, Madduri, Deepu, additional, Agha, Mounzer, additional, Stewart, A. Keith, additional, Singh, Indrajeet, additional, Zudaire, Enrique, additional, Yeh, Tzu-Min, additional, Allred, Alicia J., additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Schecter, Jordan M., additional, Jackson, Carolyn C., additional, Deraedt, William, additional, Geng, Dong, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Hossain, Farah, additional, Wang, Vickie, additional, Berdeja, Jesus G., additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

22. Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Author

Martin, Thomas, primary, Lin, Yi, additional, Agha, Mounzer, additional, Cohen, Adam D., additional, Htut, Myo, additional, Stewart, A. Keith, additional, Hari, Parameswaran, additional, Berdeja, Jesus G., additional, Madduri, Deepu, additional, Usmani, Saad Z., additional, Yeh, Tzu-Min, additional, Allred, Alicia J., additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Schecter, Jordan M., additional, Jackson, Carolyn C., additional, Deraedt, William, additional, Gries, Katharine S., additional, Fastenau, John, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene, additional, Akram, Muhammad, additional, Hossain, Farah, additional, Jakubowiak, Andrzej, additional, and Jagannath, Sundar, additional

Published
2021
Full Text
View/download PDF

23. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

Author

Berdeja, Jesus G., primary, Madduri, Deepu, additional, Usmani, Saad Zafar, additional, Singh, Indrajeet, additional, Zudaire, Enrique, additional, Yeh, Tzu-Min, additional, Allred, Alicia J., additional, Olyslager, Yunsi, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Schecter, Jordan, additional, Geng, Dong, additional, Wu, Xiaoling, additional, Carrasco-Alfonso, Marlene, additional, Rizvi, Syed, additional, Fan, Frank (Xiaohu), additional, Jakubowiak, Andrzej J., additional, and Jagannath, Sundar, additional

Published
2020
Full Text
View/download PDF

24. 535 - CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma

Author

Einsele, Hermann, van de Donk, Niels W.C.J., Arnulf, Bertrand, Schecter, Jordan M., De Braganca, Kevin C., Varsos, Helen, Deraedt, William, Tian, Hong, Vogel, Martin, Carrasco-Alfonso, Marlene, Akram, Muhammad, Wu, Xiaoling, Nesheiwat, Tonia, Mateos, Maria-Victoria, and Usmani, Saad Z.

Published
2021
Full Text
View/download PDF

25. 473 - Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Author

Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D., Htut, Myo, Stewart, A. Keith, Hari, Parameswaran, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Gries, Katharine S., Fastenau, John, Wu, Xiaoling, Carrasco-Alfonso, Marlene, Akram, Muhammad, Hossain, Farah, Jakubowiak, Andrzej, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

26. 472 - Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Author

Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John, Deraedt, William, Carrasco-Alfonso, Marlene J., Akram, Muhammad, Hossain, Farah, Crawford, Rebecca, Morrison, Ross, Doward, Lynda, Jakubowiak, Andrzej, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

27. 45 - Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study

Author

Lin, Yi, Martin, Thomas, Cohen, Adam D., Jakubowiak, Andrzej, Jasielec, Jagoda, Usmani, Saad Z., Madduri, Deepu, Agha, Mounzer, Stewart, A. Keith, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene, Akram, Muhammad, Hossain, Farah, Wang, Vickie, Berdeja, Jesus G., and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

29. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Author

Dhodapkar, Madhav V., Alsina, Melissa, Berdeja, Jesus G., Patel, Krina K., Richard, Shambavi, Vij, Ravi, Leleu, Xavier, Egan, Daniel N., Bergsagel, P. Leif, Reshef, Ran, Usmani, Saad Z, Truppel-Hartmann, Anna, Basudhar, Debashree, Thompson, Ethan, Zheng, Xirong, Eliason, Laurie, Zhong, Xiaobo, Greggio, Chiara, Tran, Sinhan, Chaudhry, Maria, Carrasco-Alfonso, Marlene J., and Siegel, David S.

Abstract

Introduction

Published
2023
Full Text
View/download PDF

32. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Author

Motzer, Robert J., Haas, Naomi B., Donskov, Frede, Gross-Goupil, Marine, Varlamov, Sergei, Kopyltsov, Evgeny, Lee, Jae Lyun, Melichar, Bohuslav, Rini, Brian I., Choueiri, Toni K., Zemanova, Milada, Wood, Lori A., Reaume, M. Neil, Stenzl, Arnulf, Chowdhury, Simon, Lim, Ho Yeong, McDermott, Ray, Michael, Agnieszka, Bao, Weichao, and Carrasco-Alfonso, Marlene J.

Published
2017
Full Text
View/download PDF

33. Genetic and epigenetic fine mapping of causal autoimmune disease variants

Author

Farh, Kyle Kai-How, primary, Marson, Alexander, additional, Zhu, Jiang, additional, Kleinewietfeld, Markus, additional, Housley, William J., additional, Beik, Samantha, additional, Shoresh, Noam, additional, Whitton, Holly, additional, Ryan, Russell J. H., additional, Shishkin, Alexander A., additional, Hatan, Meital, additional, Carrasco-Alfonso, Marlene J., additional, Mayer, Dita, additional, Luckey, C. John, additional, Patsopoulos, Nikolaos A., additional, De Jager, Philip L., additional, Kuchroo, Vijay K., additional, Epstein, Charles B., additional, Daly, Mark J., additional, Hafler, David A., additional, and Bernstein, Bradley E., additional

Published
2014
Full Text
View/download PDF

35. Additional file 1: of Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun, Jae-Lyun Lee, Jinsoo Chung, Lim, Ho, Hsi Wu, Chang, Yen, Azad, Arun, Davis, Ian, Carrasco-Alfonso, Marlene, Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Subjects
3. Good health
Abstract

Conduct of NCT00720941 and NCT01147822 and timing of key study events. Protocol amendment 4 authorized inclusion of patients from NCT01147822 for safety and efficacy analyses. FPFV = first patient first visit. Data from Motzer RJ et al. [8]. Conduct of trials NCT00720941 and NCT01147822. (PDF 111Â kb)

36. Additional file 1: of Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Author

Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun, Jae-Lyun Lee, Jinsoo Chung, Lim, Ho, Hsi Wu, Chang, Yen, Azad, Arun, Davis, Ian, Carrasco-Alfonso, Marlene, Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, and Motzer, Robert

Subjects
3. Good health
Abstract

Conduct of NCT00720941 and NCT01147822 and timing of key study events. Protocol amendment 4 authorized inclusion of patients from NCT01147822 for safety and efficacy analyses. FPFV = first patient first visit. Data from Motzer RJ et al. [8]. Conduct of trials NCT00720941 and NCT01147822. (PDF 111Â kb)

Catalog

Books, media, physical & digital resources
See catalog results